Virtual Library
Start Your Search
Yi-Lin Wu
Author of
-
+
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-048 - Clinical Impact of EGFR Mutation on Brain Metastasis in NSCLC Patients: A Meta-Regression Analysis (ID 7312)
09:30 - 09:30 | Author(s): Yi-Lin Wu
- Abstract
Background:
Though target agents like epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have shown activity in patients with brain metastasis, the impact of EGFR mutation on incidence of non-small cell lung cancer (NSCLC) with brain metastasis and treatment outcome remain inconclusive.
Method:
MEDLINE, PubMed, and EBSCO Libraries were systematically searched until August 31, 2015. Retrospective studies including investigating the correlation between EGFR mutation status with brain metastasis from NSCLC were included.
Result:
The result of the fourteen studies including 4432 patients indicated NSCLC patients with EGFR mutation have higher incidence of brain metastasis (Figure 1, odd ratio = 2.09, 95% CI: 1.72–2.53). And, EGFR mutations were associated with better survival in patients with brain metastasis from five studies though not statistically significant (Figure 2, hazard ratio = 0.47, 95% CI: 0.16–1.35). Figure 1. Meta-analysis of the association between EGFR mutation status and the risk of brain metastasis. Figure 1 Figure 2. Meta-analysis on mean overall survival among NSCLC patients with brain metastasis according to EGFR mutation status. Figure 2
Conclusion:
We found that EGFR mutation increased risk of brain metastasis but EGFR mutation might predict better survival with appropriate treatments.
-
+
P2.10 - Nursing/Palliative Care/Ethics (ID 711)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Nursing/Palliative Care/Ethics
- Presentations: 2
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.10-001 - Factors Associated with Quality of Life among Patients with Lung Cancer (ID 8710)
09:30 - 09:30 | Presenting Author(s): Yi-Lin Wu
- Abstract
Background:
Lung cancer is the third incidence and first mortality of cancer disease in Taiwan. The survival time of lung cancer patients was extended. The overall 2 year survival rate from 29% to 49.8% at National Cheng Kung University Hospital (NCKUH). Factors associated with quality of life have become the issues of focus and need to be elucidated as the improvements of medical science prolong the survival of patients with lung cancer.The purpose of this study was to describe the long-term trend on the quality of life of patients with lung cancer, and to understand the related factors.
Method:
This was a retrospective study with secondary data analysis and chart review. The study samples were lung cancer patients who were diagnosed from 2005 to 2012 at NCKUH and joined WHOQOL interview research program. We assessed personal characteristic, health status, lung cancer disease status and treatment. The authors analyzed secondary databases included the NCKUH cancer registration database and the NCKUH Cancer QoL Study database. The analyzing protocol was also approved by the institutional ethics committee. Using SAS 9.3 software, the regression models and mixed-models were constructed to explore related factors and the time trend of QoL.
Result:
Total 1887 questionnaires were included in research. The proportion of female subject was 47.7%. Figure 1
Conclusion:
The physical, psychological, environment domains and global QoL among lung cancer patients was improved over time, which showed the promising quality of treatment and care in NCKUH. The factors associated with QoL among patients with lung cancer include gender, age, married status, employment status, income, and with chronic kidney disease or brain metastasis. More resources are to be explored for patients who are single or have lower income, and special attention should be paid to patients who are unemployed, female, elder, or to under radiotherapy that would improve their QoL.
-
+
P2.10-002 - A Study on the Relation between Gender and Quality of Life for Lung Cancer Patients (ID 8885)
09:30 - 09:30 | Presenting Author(s): Yi-Lin Wu
- Abstract
Background:
Two papers showed that female lung cancer patients have poorer QoL. But others papers didn't have consistence conclusion. In author's NCKUH-10207013 study, the result showed that male patients improved more than female over time in the domains of physical, psychological and social quality of life. The purpose of this study was to understand the demographic status and characteristic of QOL in different gender. And to understand the related factors of the QOL in different gender.
Method:
The study design was to analyze secondary databases. The study samples were lung cancer patients who were diagnosed at National Cheng Kung University Hospital and joined WHOQOL interview in DOH100-TD-C-111-003 study. The databases included the cancer registration database, the diagnosis and treatment database for lung cancer, and the NCKUH quality of life database. Using SPSS and SAS 9.3 software, regression madel and mixed-models were constructed to explore the difference and related factors of quality of life between gender.
Result:
409 females and 446 males lung cancer patients were included this study. Female lung cancer patients were diagnosed with younger age, higher proportion of non-working status and single status. Female had lower score in psychological domain of QoL at 6th months after diagnosis. But female had better score than male in physical domain of QoL at 9th months after diagnosis. For the QoL details items of each domains, there were significant negative differences of female in pain, energy, active ability, sleep, daily activity, thinking, bodily image, self-esteem, negative feeling. Figure 1
Conclusion:
The larger significant differences between gender were pain and sleep of the physical domain, and bodily image and negative feelings of the psychological domain. The results of this study could understand the differences of QoL between gender. More resources and care plans should to be explored for different gender to improve their QoL and prevention QoL decrease.
-
+
P3.05 - Early Stage NSCLC (ID 721)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Early Stage NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.05-004 - The Impact of EGFR Mutations on Incidence and Survival of NSCLC Patients with Brain Metastasis: a Single Center Retrospective Study (ID 8322)
09:30 - 09:30 | Author(s): Yi-Lin Wu
- Abstract
Background:
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite advances in systemic therapy and improvements in survival for advanced non-small cell lung carcinoma (NSCLC), brain metastasis (BM) remained an important etiology of morbidity and mortality. This study was designed to analyze the association between the epidermal growth factor receptor (EGFR) mutation status and the incidence of brain metastases (BM) and associated survival.
Method:
We retrospectively investigated the medical records of 491 patients diagnosed with NSCLC stage I to stage III from 2004 to 2015, who were tested for EGFR mutations. The time from the diagnosis of advanced NSCLC to the development of BM and the overall median survival after BM development were evaluated and compared by EGFR mutation status.
Result:
Seventy-eight of 491 patients developed BM. From 280 patients had EGFR mutations, 49 patients developed BM and 29 of 211 patients harboring wild-type EGFR developed BM. Comparing with wild-type EGFR group, the incidence of subsequent BM was statistically higher in patients with EGFR mutations [49 (17.5%) vs. 29 (13.7%), p=0.023]. Patients with EGFR mutations also demonstrated the trend with longer overall survival (OS) after BM diagnosis than patients with wild-type EGFR (17.8 v.s. 12.2 months, HR:0.79 , 95% CI: 0.45-1.40, p = 0.416) (Figure 1). Figure 1
Conclusion:
Our data suggested that EGFR mutation is a predictive risk factor for the development of brain metastasis. Though there is no statistical significance, NSCLC patients with EGFR mutation and brain metastasis tend to have longer survival than those with EGFR wild type.
